Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Current Assets (2019 - 2025)

aTYR PHARMA's Current Assets history spans 7 years, with the latest figure at $80.2 million for Q4 2025.

  • For Q4 2025, Current Assets fell 2.1% year-over-year to $80.2 million; the TTM value through Dec 2025 reached $80.2 million, down 2.1%, while the annual FY2025 figure was $80.2 million, 2.1% down from the prior year.
  • Current Assets reached $80.2 million in Q4 2025 per ATYR's latest filing, down from $93.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $121.6 million in Q3 2021 to a low of $46.4 million in Q2 2021.
  • Average Current Assets over 5 years is $91.5 million, with a median of $91.7 million recorded in 2024.
  • Peak YoY movement for Current Assets: soared 219.63% in 2021, then plummeted 30.38% in 2022.
  • A 5-year view of Current Assets shows it stood at $113.6 million in 2021, then dropped by 28.79% to $80.9 million in 2022, then grew by 27.35% to $103.0 million in 2023, then decreased by 20.43% to $82.0 million in 2024, then decreased by 2.1% to $80.2 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Current Assets are $80.2 million (Q4 2025), $93.0 million (Q3 2025), and $87.5 million (Q2 2025).